

Journal Club Spotlights: Current Advancements in Non-Small Cell Lung Cancer



Key Concepts

CHIO3: Chemotherapy combined with immune checkpoint inhibitor for operable stage IIIA/B (N2) Non-Small cell lung cancer (AFT-46)

- Neoadjuvant chemotherapy in combination with durvalumab provides high rates of mediastinal nodal (N2+) clearance and high rates of complete surgical resection in a historically challenging patient population with surgically resectable stage IIIA non-small cell lung cancer
- Neoadjuvant chemotherapy combined with immunotherapy provided robust survival benefits for event-free survival and overall survival at 18 months with low rates of toxicity and overall low rates of grade ≥ 3 adverse events